PurMinds Announces Clinical Validation Collaboration with SpectroChip and Taiwan's Kaohsiung Municipal Siaogang Hospital

Five-year collaboration framework aims to advance point-of-care diagnostics, clinical performance evaluation, and precision-medicine applications

LAS VEGAS and TORONTO, Oct. 14, 2026 /PRNewswire/ -- PurMinds Enterprises, Inc. (formerly Pacific Software, Inc.) (OTC: PFSF) ("PurMinds" or the "Company") today announced the signing of a collaboration agreement with SpectroChip Inc. ("SpectroChip"), a Taiwan-based developer of photonic-chip sensing and portable testing technologies, and Kaohsiung Municipal Siaogang Hospital ("Siaogang Hospital"), operated by Kaohsiung Medical University, to support teaching, research, and clinical validation of point-of-care (POC) diagnostic technologies and testing solutions.

The collaboration brings together SpectroChip's photonic chip-based portable testing technology, PurMinds' SwiftLab^TM Platform and precision-medicine solutions, and Siaogang Hospital's clinical research capabilities. The parties intend to establish the joint "PurMinds / SpectroChip Global Clinical Validation Testing Center" for teaching, research, and clinical-validation activities, as a framework for evaluating diagnostic performance, assessing testing workflows, and advancing research into continuously improved POC performance, subject to review by an institutional review board (IRB), institutional approvals and applicable regulatory requirements.

Connecting diagnostic technology with clinical research

PurMinds' SwiftLab^TM Platform is built around a full-spectrum laboratory-grade spectrometer shrunk onto a single, highly advanced photonic chip and housed inside the SpectroCision™ SPU-D100, a portable reader small enough to carry anywhere.  The platform is designed to turn a low-cost lateral-flow cassette from a faint yes-or-no line into a lab-grade quantitative result in five minutes or less, in clinics, pharmacies, community health centers, and at the patient's bedside.  Clinical research and performance evaluation are important steps in assessing how diagnostic technologies and testing solutions perform in intended-use settings.

Under the collaboration, the parties will contribute complementary capabilities:

• PurMinds will lead the precision-medicine applications, clinical research collaboration, and access to international research and industry resources in its overall global commercialization strategy.
• SpectroChip will provide its photonic chip-based testing technology, together with technical documentation, training, and related support.
• Siaogang Hospital will provide an institutional setting for approved teaching, research, and clinical-validation activities, including research design, performance evaluation, testing-workflow assessment, and talent development.

Specific research projects will be established through separate written arrangements defining their scope, responsibilities, timelines, funding, and deliverables. Activities involving human participants, specimens, personal data, or medical-device clinical studies will proceed in accordance with applicable ethical, regulatory, and institutional requirements. The designation does not represent the establishment of a separate legal entity or dedicated physical facility.

By connecting technology development with institutional research capabilities, the collaboration aims to create a foundation for evaluating diagnostic applications and supporting PurMinds' development and commercialization activities.

Research and education support

Under the collaboration framework, SpectroChip has committed to providing Siaogang Hospital with NT$3 million (about US$94,000) in teaching and research funding over five years, generally at NT$600,000 per year, subject to the applicable agreement and institutional procedures. The funding is intended to support approved educational and research activities, which may include research consumables, testing, equipment maintenance, data analysis, research personnel, training, and academic exchange. The collaboration framework preserves the hospital's independence in its professional, clinical, research, and procurement decisions.

"This collaboration brings together SpectroChip's cutting-edge photonic chip technology, Siaogang Hospital's clinical research environment and PurMinds' precision-medicine platform and commercialization strategy," said Janet Qi, Founder and Chief Executive Officer of PurMinds.  "Given the full-spectrum spectrometry embedded in our platform and its potential to develop an extended catalog of testing items, our vision is to connect with clinically relevant testing applications and the research needed to evaluate them."

"For over two decades, our team has worked to miniaturize spectrometer technology and make quantitative analysis possible through our proprietary photonic chip technology. This collaboration with PurMinds and Siaogang Hospital represents an important opportunity to bring our technology into a structured clinical research environment, where diagnostic performance and testing workflows can be systematically evaluated," said Dr. Cheng-Hao (Kevin) Ko, founder of SpectroChip and inventor of the SwiftLab Platform.

"Collaboration between healthcare institutions, technology developers, and market integrators is important to the responsible evaluation of emerging diagnostic technologies. We look forward to supporting appropriate teaching and research activities, evaluating diagnostic performance under approved study protocols, and contributing clinical perspectives to the development of point-of-care testing. All research activities will be conducted in accordance with applicable ethical, institutional, and regulatory requirements," said Chih-Hsing Hung, MD, PhD, Dean of Kaohsiung Municipal Siaogang Hospital.

About PurMinds Enterprises, Inc.

PurMinds Enterprises, Inc. (OTC: PFSF) exists to close the gap between precise answers from a central laboratory, which arrive days after the patient has gone home, and fast answers from rapid tests, which offer a single faint "yes or no" line and nothing more.  At the heart of its SwiftLab™ Platform is a full-spectrum, laboratory-grade spectrometer shrunk onto a photonic chip and housed inside the SpectroCision™ SPU-D100, a fully portable reader small enough to carry anywhere without the need for recalibration. The platform is designed to turn a low-cost lateral-flow cassette from a faint yes-or-no line into a quantitative result in five minutes or less. That capability stands on 17 peer-reviewed papers, 15 granted patents, and a trade-secret manufacturing process refined over 20 years.

One reader delivers every use case: comprehensive blood testing, veterinary diagnostics, roadside drug intoxication screening, specialized multiplex panels, and pathogen testing, all run on the same SpectroCision reader.  Only the low-cost test cassette changes.  Clinical uses are subject to regulatory clearance in each market. PurMinds holds an exclusive license to the SwiftLab Platform for the health and safety fields worldwide.

PurMinds began with a single ambition: to treat the brain.  A company that means to treat the brain must be able to measure disease progression and therapeutic intervention, repeatedly, cheaply, and wherever the patient is, and that need brought PurMinds and SpectroChip together to build a quantitative point-of-care neurology panel.  PurMinds holds its two drug candidates in a wholly owned subsidiary, PurQuest™ Therapeutics: PUR102, a botanical psilocybin, and PUR501, a preclinical non-hallucinogenic neuroplastogen.

The SpectroCision reader and PurMinds cassettes have not been cleared or approved by the United States Food and Drug Administration or licensed by Health Canada and are not available for clinical use in the United States or Canada.

For more information, visit www.purminds.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. These statements include, but are not limited to, statements concerning the collaboration among PurMinds, SpectroChip, and Siaogang Hospital; anticipated research, testing, and clinical-validation activities; the potential applications of point-of-care diagnostic technologies; the development and commercialization of diagnostic products; and the Company's business strategy.

Forward-looking statements are based on current expectations, assumptions, and estimates and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks include the ability to implement planned research activities, obtain required institutional and ethics approvals, meet regulatory requirements, demonstrate product performance, secure resources, and establish commercial relationships; that regulators may not clear, waive, or license the Company's products, or may do so later or with narrower claims than expected; that the Company depends on licenses and collaborations with third parties that could be lost or restricted; that the Company requires additional capital and may not obtain it on acceptable terms; and that the Company is a former shell company with a limited operating history, has not yet published audited financial statements, and has a small public float; as well as competition and general economic and market conditions.

The collaboration does not guarantee any particular research outcome, regulatory authorization, product commercialization, or financial result. No assurance can be given that the parties will complete planned activities within anticipated timelines or achieve their intended objectives. Readers should not place undue reliance on forward-looking statements. Except as required by applicable law, PurMinds undertakes no obligation to update forward-looking statements following the date of this release.  This press release is not an offer to sell or a solicitation of an offer to buy any security.

SOURCE PurMinds Enterprises, Inc.